

## **Genome-Wide Sequencing as a First-Tier Screening Test for Short Tandem Repeat Expansions**

Indhu-Shree Rajan-Babu<sup>1\*</sup>, Junran Peng<sup>1</sup>, Readman Chiu<sup>2</sup>, IMAGINE Study<sup>1</sup>, CAUSES Study<sup>1</sup>, Arezoo Mohajeri<sup>1</sup>, Egor Dolzhenko<sup>3</sup>, Michael A. Eberle<sup>3</sup>, Inanc Birol<sup>1,2</sup>, Jan M. Friedman<sup>1</sup>

<sup>1</sup>Department of Medical Genetics, University of British Columbia, and Children's & Women's Hospital, Vancouver, BC, Canada

<sup>2</sup>Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada

<sup>3</sup>Illumina Inc, San Diego, CA, US

\*Address correspondence to Indhu Shree Rajan Babu, Ph.D., Department of Medical Genetics, University of British Columbia, British Columbia, Vancouver, Canada. Tel: +1-604-875-2000 ext. 5980, Email: [indhu.babu@bcchr.ca](mailto:indhu.babu@bcchr.ca)

1 **ABSTRACT**

2 Short tandem repeat (STR) expansions cause several neurological and neuromuscular disorders.  
3 Screening for STR expansions in genome-wide (exome and genome) sequencing data can enable  
4 diagnosis, optimal clinical management/treatment, and accurate genetic counselling of patients  
5 with repeat expansion disorders. We assessed the performance of lobSTR, HipSTR, RepeatSeq,  
6 ExpansionHunter, TREDPARSE, GangSTR, STRetch, and exSTRa – bioinformatics tools that  
7 have been developed to detect and/or genotype STR expansions – on experimental and simulated  
8 genome sequence data with known STR expansions aligned using two different aligners, Isaac  
9 and BWA. We then adjusted the parameter settings to optimize the sensitivity and specificity of  
10 the STR tools and fed the optimized results into a machine-learning decision tree classifier to  
11 determine the best combination of tools to detect full mutation expansions with high diagnostic  
12 sensitivity and specificity. The decision tree model supported using ExpansionHunter’s full  
13 mutation calls with those of either STRetch or exSTRa for detection of full mutations with  
14 precision, recall, and F1-score of 90%, 100%, and 95%, respectively.

15 We used this pipeline to screen the BWA-aligned exome or genome sequence data of 306  
16 families of children with suspected genetic disorders for pathogenic expansions of known disease  
17 STR loci. We identified 27 samples, 17 with an apparent full-mutation expansion of the *AR*,  
18 *ATXN1*, *ATXN2*, *ATXN8*, *DMPK*, *FXN*, *HTT*, or *TBP* locus, nine with an intermediate or  
19 premutation allele in the *FMRI* locus, and one with a borderline allele in the *ATXN2* locus. We  
20 report the concordance between our bioinformatics findings and the clinical PCR results in a  
21 subset of these samples. Implementation of our bioinformatics workflow can improve the  
22 detection of disease STR expansions in exome and genome sequence diagnostics and enhance  
23 clinical outcomes for patients with repeat expansion disorders.

## 24 INTRODUCTION

25 Expansions of short tandem repeats (STRs; tandemly repeated arrays of 1–6 base pair (bp)  
26 sequence motifs<sup>1</sup>) can cause several neurological and neuromuscular disorders<sup>2</sup>. Accurate  
27 genotyping (i.e., the determination of the number of copies of repeat units in an STR) is critical  
28 to the molecular diagnosis of STR expansion disorders as repeat length usually shows a positive  
29 correlation with severity and negative correlation with age of onset of clinical symptoms<sup>3</sup>.  
30 Repeat length also determines an STR's allelic class (normal, NL; intermediate, IM;  
31 premutation, PM; or full-mutation, FM), which may differ with respect to associated disease  
32 phenotype<sup>3;4</sup>. For example, the *FMRI* (MIM 309550) PM (55–200 CGG repeats) increases the  
33 risk for primary ovarian insufficiency (MIM 311360) and tremor/ataxia syndrome (MIM  
34 300623). In contrast, *FMRI* FM (>200 CGG repeats) causes fragile X syndrome (MIM 300624),  
35 the most frequent Mendelian cause of intellectual disability<sup>5</sup>. PM and IM (also known as  
36 “mutable NL”) alleles that are meiotically unstable can expand into pathogenic FM in a single  
37 generation, while NL alleles rarely, if ever, do so<sup>6;7</sup>. Expanded alleles tend to further increase in  
38 repeat length during intergenerational transmission, and, as a result, genetic anticipation (the  
39 earlier and more severe manifestation of disease symptoms with each successive generation) is  
40 common in repeat expansion disorders<sup>8</sup>.

41 Clinical laboratories typically use polymerase chain reaction (PCR) or Southern blot (SB)  
42 (alone or in combination) to characterize expansions at known disease STR loci<sup>9</sup>. Although  
43 highly sensitive in detecting and genotyping STR expansions, PCR and SB tests have several  
44 limitations. They are time- and labor-intensive, require extensive optimization, and do not permit  
45 concurrent analyses of more than a handful of STR loci. Next-generation sequencing (NGS), on  
46 the other hand, enables exome- and genome-wide characterization of STRs. Several algorithms

47 have recently been developed to analyse STRs in NGS data<sup>1; 10-14</sup>. The incorporation of  
48 bioinformatics tools to screen for STR expansions may permit the diagnosis of repeat expansion  
49 disorders during routine diagnostic exome or genome sequencing, allow accurate genetic  
50 counseling of affected individuals and their families, and improve clinical outcomes.

51 The currently-available STR analysis algorithms have different attributes that determine  
52 their utility and sensitivity in detecting and characterizing repeat expansions in NGS data (Table  
53 1). Methods like STRetch<sup>11</sup> and exSTRa<sup>12</sup> identify STR expansions via case-control analysis,  
54 with a caveat of either underestimating the repeat lengths of some expanded STRs<sup>11</sup> or not  
55 genotyping STRs<sup>12</sup>. Methods that genotype STRs are known to perform better across certain  
56 repeat length ranges depending on the read type evidence considered. For instance, tools relying  
57 on reads that fully encompass an STR (“spanning reads”) to compute repeat length<sup>15-17</sup> can size  
58 alleles within the length of an Illumina read (125–150 base pairs [bp]) but they perform poorly in  
59 detecting pathogenic FM expansions that exceed read length. More recent methods<sup>1; 10; 18; 19</sup> that  
60 leverage on additional read types such as flanking or partially flanking reads (those that map to  
61 unique flanking sequences), in-repeat reads (IRR; those that are entirely composed of STRs with  
62 a mate that maps to the STR’s flanking sequence), and/or IRR pairs (both reads of a pair  
63 mapping to the STR) can size STRs that exceed read length. ExpansionHunter<sup>10; 19</sup> and  
64 GangSTR<sup>18</sup>, in particular, enable the recovery of IRR and IRR pairs, which originate from an  
65 expanded STR but may incorrectly map to other STR (or “off-target”) regions with longer tracts  
66 of the same repeat motif. By allowing the inclusion of off-target sites (OTS) in analysis,  
67 ExpansionHunter and GangSTR facilitate sizing STRs that are longer than an Illumina  
68 sequencing library fragment length (350–500 bp).

69 In terms of utility, some of these methods can analyse STRs in both exome sequencing  
70 (ES) and genome sequencing (GS) data<sup>11; 12; 18</sup>, while others are designed specifically for GS<sup>1; 10;</sup>  
71 <sup>19</sup>. Some tools have specific NGS data requirements; for example, ExpansionHunter is designed  
72 for PCR-free GS, and exSTRa has only been extensively tested on bowtie-2<sup>20</sup> alignments. Also,  
73 most methods have been recognized to perform less optimally on GC-rich STR expansions<sup>10; 12</sup>.  
74 These varied attributes and performance characteristics have led to the acknowledgment that a  
75 single bioinformatics tool is less likely to be able to identify pathogenic STR expansions of all  
76 repeat lengths and sequence content/composition in NGS data<sup>12</sup>. Recently, Tankard *et al*  
77 recommended a consensus calling approach using at least two out of four tools (TREDPARSE<sup>1</sup>,  
78 ExpansionHunter, STRetch, and exSTRa) to characterize expansions of known disease STRs<sup>12</sup>.  
79 However, it is not clear which of these (or other) STR methods alone or in combination yield  
80 optimal sensitivity and specificity.

81 In this study, we employed a decision tree classifier to identify the optimal tool(s) for  
82 classifying expanded FM and non-expanded alleles at known disease STR loci with high  
83 accuracy, precision, recall, and F1-score. We performed our analysis on the STR calls from nine  
84 different tools<sup>1; 10-12; 15; 17-19; 21</sup> made on the GS data of patients with well-characterized STR  
85 expansions in one of eight different loci (*AR*, *ATN1*, *ATXN1*, *ATXN3*, *DMPK*, *FMRI*, *FXN*, or  
86 *HTT*)<sup>10</sup> and simulated GS data harboring expansions of the GC-rich *FMR2* or *C9orf72* STR loci.  
87 These data were aligned using two different aligners, Isaac<sup>22</sup>, an ultra-fast aligner, and BWA-  
88 MEM<sup>23</sup>, recommended by the GATK best practices guidelines<sup>24</sup> and widely used in GS  
89 studies<sup>25</sup>, to see if the choice of the aligner influences the performance of the STR methods.  
90 First, we tested the classifier on the results generated by the implementation of tools using  
91 default parameter settings. We then tweaked several parameters, such as the inclusion/exclusion

92 of OTS and using a different FM repeat length threshold to define expansions at selected loci and  
93 implementation of exSTRa with a control cohort, to optimize the sensitivity and specificity of the  
94 STR tools included in this study. Once we established the parameters that yielded the best  
95 results, we input the data generated with these settings into the classifier and found a significant  
96 improvement in our model's ability to detect FMs compared to our default parameter assessment.  
97 We then applied our decision tree model of STR algorithms to screen for expansions in known  
98 disease STR loci in the GS or ES data of 306 families (patient-parent trios (patient and both  
99 biological parents) or quads (patient, sibling, and both biological parents)) with a proband who is  
100 suspected to have a genetic disorder.

## 101 **METHODS AND APPROACHES**

### 102 **GS Datasets with a Known Repeat Expansion**

103 The GS datasets with a known repeat expansion analysed in this study include the BWA and  
104 Isaac alignments of: 1) the European Genome-phenome archive (EGA) dataset<sup>10</sup>  
105 (EGAD00001003562), which consisted of data from 118 PCR-free GS of Coriell samples, each  
106 with an *AR*, *ATN1*, *ATXN1*, *ATXN3*, *DMPK*, *FMRI*, *FXN*, or *HTT* expansion (Supplementary  
107 Table 1a); and 2) *C9orf72* or *FMR2* expansions of varying repeat lengths simulated using the  
108 ART NGS read simulator<sup>26</sup> (Supplementary Table 1b) as outlined in Supplementary Methods.  
109 The simulated GS data were included in our analysis to assess the performance of the STR  
110 algorithms on expansions of extremely high GC content (100%) that may be refractory to  
111 detection.

## 112 **Patient Cohorts and ES and GS Data Generation**

113 The patient cohorts screened for known STR expansions in this study consist of the ES data of  
114 146 trios or quads from the Clinical Assessment of the Utility of Sequencing and Evaluation as a  
115 Service (CAUSES) study and the GS data of 160 trios or quads from the Integrated  
116 Metabolomics And Genomics In Neurodevelopment (IMAGINE) or CAUSES studies. Subjects  
117 enrolled in the CAUSES study were children who were suspected on clinical grounds to have a  
118 single gene disorder but in whom conventional testing had not identified a genetic cause.  
119 Subjects enrolled in the IMAGINE study had impairment of motor function with onset before  
120 birth or within the first year of life and additional clinical features that made perinatal  
121 complications such as hypoxia or intracranial hemorrhage an unlikely explanation for their  
122 problems. Most of the subjects enrolled in the CAUSES or IMAGINE studies had intellectual  
123 disability. The ES or GS data from the unaffected parents were used to verify the inheritance or  
124 unstable transmission of variants. These studies were approved by the Institutional Review  
125 Board of the BC Children's and Women's Hospital and the University of British Columbia  
126 (H15-00092 and H16-02126).

127 The trio/quad ES data were sequenced by Ambry Genetics (Aliso Viejo, United States),  
128 Centogene (Rostock, Germany), or BC Cancer Agency Genome Sciences Centre (Vancouver,  
129 Canada) to a mean coverage of ~60x. The library preparation protocols and sequencers used to  
130 generate the trio/quad ES data are described in Supplementary Table 2.

131 The median coverage of the trio/quad GS data ranged from 36 to 80x and was generated  
132 by the McGill University and Genome Quebec Innovation Centre (Quebec, Canada). GS libraries  
133 were prepared using the NxSeq® AmpFREE Low DNA Library Kit Library Preparation Kit and

134 Adaptors (Lucigen, Wisconsin, US) or xGen Dual Index UMI Adapters (Integrated DNA  
135 Technologies, Coralville, US) and sequenced on an Illumina HiSeqX sequencer.  
136 The paired-end reads (125 or 150 bp) of both the ES and GS datasets were aligned to the  
137 UCSC hg19 human reference genome using BWA-MEM, and duplicates were marked with  
138 Picard<sup>27</sup>. All patient ES data underwent single-nucleotide variant (SNV) and indel analysis, and  
139 145 out of the 146 trios or quads included in this study had no clinically-relevant SNV/indel  
140 variants. We also analysed the ES data of a quad with known myotonic dystrophy (Type 1; DMI  
141 – MIM 160900) in the proband and his mother as a positive control. Our patient GS data  
142 underwent SNV, indel, structural, and mitochondrial variant analysis, with a causal variant  
143 identified in about half of the trios (unpublished data). We included the GS data of all cases in  
144 this study.

#### 145 **Bioinformatics Tools for STR Analysis**

146 The STR analysis tools implemented in this study include lobSTR<sup>15</sup>, HipSTR<sup>28</sup>, RepeatSeq<sup>17</sup>,  
147 TREDPARSE<sup>1</sup>, ExpansionHunter<sup>10; 19</sup>, GangSTR<sup>18</sup>, STRetch<sup>11</sup>, and exSTRa<sup>12</sup>. The key features  
148 of these tools and the commands and parameters used to execute them are described in Table 1  
149 and Supplementary Table 3, respectively. We first used ExpansionHunter (EH) version 2 in this  
150 study<sup>10</sup> and later included the improved iteration (version 3) of EH optimized to genotype STRs  
151 with complex or mixed repeat motifs<sup>19</sup>.

#### 152 **Disease STR Catalogs**

153 The STR analysis tools assess known disease STRs included within a pre-defined catalog  
154 supplied by the authors. The known pathogenic STR loci included in these catalogs, as well as  
155 their allelic categories and corresponding repeat lengths, are summarized in Supplementary  
156 Table 4. Notably, the region files for ExpansionHunter only included pre-defined OTS for *FMRI*



157 and *C9orf72* loci, while GangSTR included OTS in the region files of all 12 pathogenic STR loci  
158 provided with the tool. Some of the region files of known disease STRs analysed in this study  
159 (*AR*, *ATNI*, *FXN*, and *FMR2*) were missing for GangSTR. Therefore, we added these loci and  
160 included their OTS as described in Mousavi *et al.* (2019)<sup>13</sup>.

### 161 **Interpretation of FMs and non-FMs**

162 The data from the genotyping methods were classified as “FM” if the estimated repeat lengths of  
163 the STRs exceeded their respective FM thresholds (Supplementary Table 4). STRetch and  
164 exSTRa calls were classified as “FM” if the *p*-values post-multiple-testing-adjustment were  
165 significant (<0.05). For STRetch, we used the control file (containing data from 143 healthy  
166 individuals) provided with the tool.

### 167 **Decision Tree Classification**

168 Decision tree analysis is a supervised machine learning (ML) classification method<sup>29</sup>. We  
169 employed this approach to infer the best model or the best combination of STR analysis tools to  
170 detect FM expansions with optimal sensitivity and specificity. We used the Python Scikit-Learn  
171 ML library<sup>30</sup> to implement the decision tree classifier and used the STR calls from the  
172 EGA/simulated GS to train and test the classifiers on the data from the Isaac and BWA  
173 alignments.

174 For our preliminary decision tree analysis, we used the outputs generated using the  
175 default parameters for each of the STR analysis tools. We compiled the results generated by the  
176 STR analysis tools on the Isaac and BWA-aligned GS data. We labeled the EGA and simulated  
177 genome’s true STR expansion status or class label (FM or non-FM for a given locus).  
178 Essentially, the single known or characterized STR expansion in each of the EGA and simulated  
179 genomes was assigned to the “FM” class, while the status of the other STR loci was assigned to

180 “non-FM”. The data from the STR callers were then transformed into binary flags: 1 indicating  
181 at least one of the two alleles was called as “FM”, and 0 indicating both alleles were “non-FM”.  
182 From there, we removed all rows with missing values and supplied the data to the classifier. We  
183 divided our dataset into 80 and 20% to train and test the classifier, respectively, and then  
184 implemented the classifier. We used the Gini index approach to ascertain the efficiency of an  
185 attribute (i.e., the STR caller) in differentiating samples belonging to the FM and non-FM  
186 classes. To evaluate the performance of the classifier, we extracted different metrics, including  
187 precision (true positives TP/(TP + false positives [FP])), recall (TP/(TP + false negatives [FN])),  
188 accuracy, and F1-score ( $2 * ((\text{precision} * \text{recall}) / (\text{precision} + \text{recall}))$ ), and analysed the receiver  
189 operating characteristic (ROC) curve, a ratio of sensitivity (TP/(TP + FN)) and inverted  
190 specificity ( $1 - (\text{TN} / (\text{TN} + \text{FP}))$ ), and the precision-recall curve, a ratio of precision and recall or  
191 sensitivity. To avoid over-fitting of the data and to evaluate the robustness of the classifier, we  
192 performed 10-fold cross-validation on the training dataset and identified the best model for  
193 targeted disease STR analysis in both Isaac and BWA-aligned GS data.

194 We next ascertained whether tweaking some of the parameters would improve the  
195 performance of the STR analysis tools and the resultant decision tree model. First, we assessed  
196 the performance of ExpansionHunter with OTS on selected STR loci that are known to harbor  
197 expansions exceeding sequencing fragment lengths. This was to retrieve unmapped and  
198 mismapped IRR/IRR pairs and improve the repeat length estimation and detection of FMs.  
199 Second, we used a PM or IM repeat length threshold instead of FM threshold for *FMR1* and  
200 *FMR2* STR loci to classify expanded alleles and documented the sensitivity as well as the FP  
201 rates of the genotypers. Third, we tested exSTRa’s performance on BWA-aligned GS with  
202 control data from a cohort of 100 healthy individuals. We could not perform a similar analysis on

203 Isaac-aligned GS due to the lack of Isaac-aligned GS data of healthy subjects. We carefully  
204 evaluated how these parameter tweaks influenced the performance of the STR analysis tools and  
205 selected the optimized outcomes to rerun our decision tree classifier. The precision, recall,  
206 accuracy, and F1-score metrics of this newer model generated on the test dataset and cross-  
207 validation on the training dataset were then compared to our preliminary decision tree analysis  
208 with default parameters.

### 209 **Screening for Known Disease STR Expansions in Patient Data**

210 Finally, we screened our patient trio/quad ES and GS data for known disease STR expansions  
211 using the tools identified by the classifier. Of the probands analysed in this study, 60 have had  
212 clinical *FMRI* STR testing, three have had clinical SCA STR panel tests, one has had a clinical  
213 *FXN* STR test, and four others have had clinical *DMPK* STR tests. All of these clinical PCR-  
214 based STR tests were negative for a pathogenic expansion, except for a confirmed *DMPK* FM in  
215 a proband and his mother. All individuals who were expansion-negative at the tested locus were  
216 used as negative controls.

217 For all the expanded STRs identified in the patients, we analysed the parental genotype  
218 calls to verify the inheritance or unstable transmission of the alleles. Subjects with potential  
219 expansions of known disease STRs were identified for orthogonal validation to ascertain the  
220 specificity of our decision tree. Molecular testing (PCR and capillary electrophoresis) of some of  
221 the identified STR candidates was performed by Centogene (Germany).

## 222 RESULTS

### 223 Performance of STR Algorithms on Isaac versus BWA-aligned GS Data

224 The lobSTR, HipSTR, RepeatSeq, EH versions 2 and 3, GangSTR, TREDPARSE, STRetch, and  
225 exSTRa results of Isaac- and BWA-aligned EGA and simulated GS data are shown in  
226 Supplementary Tables 5 and 6, respectively. The spanning-read-only algorithms (lobSTR,  
227 HipSTR, and RepeatSeq) did not detect any FMs in either Isaac- or BWA-aligned GS data, as  
228 expected. Therefore, we omitted these tools from all subsequent analyses.

229 The sensitivity of EH\_v2 and EH\_v3, GangSTR, TREDPARSE, STRetch, and exSTRa  
230 run with default parameters in detecting FMs in Isaac- and BWA-aligned GS is summarized in  
231 Table 2. EH\_v2 and EH\_v3, TREDPARSE, and STRetch exhibited consistent performance and  
232 had a sensitivity of ~70% in both Isaac and BWA alignments. GangSTR's sensitivity was better  
233 on Isaac (55%) compared to BWA (38%) alignments. In marked contrast, exSTRa detected more  
234 FMs in the BWA (88%) than Isaac (56%) alignments (see Supplementary Figures 1a and 1b for  
235 exSTRa's plots on Isaac- and BWA-aligned GS, respectively). On Isaac-aligned data, STRetch,  
236 EH\_v2, and EH\_v3 detected the most FMs, followed by TREDPARSE, exSTRa, and GangSTR.  
237 On BWA-aligned data, exSTRa detected the most FMs, followed by STRetch, EH\_v2, EH\_v3,  
238 TREDPARSE, and GangSTR. Notably, although exSTRa and STRetch detected more FMs, they  
239 also had the most FP calls.

240 All FMs missed by the genotypers were under-sized and classified incorrectly as PM, IM,  
241 or NL (Supplementary Tables 7a and 7b). Additional results on the performance of the  
242 genotypers in classifying NL, IM, and PM alleles are included in Supplementary Tables 8 and 9  
243 and Supplementary Results. Among the analysed STR loci, *FMR1*, *FMR2*, and homozygous  
244 *FXN* FMs were particularly refractory to detection (Supplementary Tables 7a and 7b).

## 245 **Decision Tree Classification**

246 We first trained and tested the decision tree classifier on the generated default-parameter results  
247 of EH\_v2, EH\_v3, GangSTR, TREDPARSE, STRetch, and exSTRa. After removing the rows  
248 with missing values, the compiled STR calls of the Isaac- and BWA-aligned EGA and simulated  
249 GS datasets had 1238 and 1232 rows (one row per sample per STR locus), respectively. In Isaac-  
250 aligned data, EH\_v2, which had the lowest Gini impurity or performed the best in classifying  
251 alleles was assigned to the root node (node #0) and correctly classified 47 out of 66 FMs and 918  
252 out of 924 non-FMs in the training dataset (Supplementary Figure 2a). STRetch (node #1) and  
253 EH\_v3 (node #11) detected one of the FMs missed by EH\_v2. In the test dataset, the decision  
254 tree model had precision, recall, and F1-score of 100, 90, and 95%, respectively, to detect FMs;  
255 for non-FMs, the precision, recall, and F1-score were 99, 100, and 100%, respectively. The ROC  
256 and precision-recall plots are shown in Supplementary Figure 2b. The 10-fold cross-validation of  
257 this model on the training dataset yielded a ROC\_AUC (Area Under the Curve) of  $85.48 \pm$   
258  $12.58\%$  (mean  $\pm$  standard deviation).

259 In the BWA-aligned data, EH\_v3 at the root node correctly classified 43 out of 60 FMs  
260 and 921 out of 925 non-FMs in the training dataset, with exSTRa and GangSTR recovering one  
261 of the FMs missed by EH\_v3 (Supplementary Figure 3a). The precision, recall, and F1-score to  
262 detect FMs and non-FMs in the test data were 95, 81, and 88% and 98, 100, and 99%,  
263 respectively. The ROC and precision-recall curves are shown in Supplementary Figure 3b. The  
264 ROC\_AUC metric of the model's 10-fold cross-validation on the training dataset was  $86.24 \pm$   
265  $8.38\%$ .

266 In both Isaac and BWA analyses, nearly five out of the six features (STR tools)  
267 contributed to the performance of the model (Supplementary Figures 2c and 3c), led by either

268 EH\_v2 or EH\_v3. The sensitivity for detecting FMs in BWA-aligned data was slightly lower  
269 compared to the Isaac analysis. Overall, the decision tree classifier on the Isaac and BWA test  
270 datasets generated using the default-parameter settings missed 10 to 20% of the FMs. To  
271 improve the detection sensitivity, we evaluated some parameters that we believed might help  
272 capture more of the true FMs.

273 *Tested Parameters:* First we tested the effect of including OTS in the detection of FMs. While  
274 GangSTR's region files included OTS for all analysed loci, the author-supplied JSON files of  
275 EH did not include OTS for *DMPK*, *FXN*, or *FMR2* loci, which are known to harbor expansions  
276 exceeding fragment lengths. In our initial EH run without OTS, we noted reduced sensitivity in  
277 the detection of *FXN* and *FMR2* FMs (Supplementary Table 7). Therefore, we added OTS for  
278 analysing these loci with EH\_v2, which helped identify two out of three *FMR2* expansions in  
279 both Isaac- and BWA-aligned data (Supplementary Table 10). For the *FXN* locus, there was no  
280 improvement in sensitivity, highlighting the general limitation of the genotypers in reliably  
281 detecting homozygous *FXN* FM expansions. Second, because the GC-rich expansions such as  
282 those at the *FMRI* locus tend to be under-sized owing to reduced coverage even in PCR-free  
283 Illumina GS datasets<sup>10</sup>, we used an IM (54 repeats) and PM (60 repeats) repeat length threshold  
284 for *FMRI* and *FMR2* loci, respectively, instead of their FM threshold (both at 200 repeats). With  
285 this tweak, EH\_v2 and EH\_v3 detected all *FMRI* and *FMR2* FMs in Isaac- as well as BWA-  
286 aligned data (Table 3). TREDPARSE detected 83 to 89% of the *FMRI* FMs, but none of the  
287 *FMR2* FMs, while GangSTR detected 16 to 22% of the *FMRI* FMs and none of the *FMR2* FMs.  
288 The identified FPs in this analysis include the known *FMRI* PMs and a few borderline *FMRI* IM  
289 alleles that are closer to the threshold. Lastly, we hypothesized that adding data from a control  
290 cohort to exSTRa's analysis of BWA alignments would further improve its FM detection

291 potential. With controls, exSTRa yielded a sensitivity of 95% and detected all homozygous *FXN*  
292 FM expansions, as well as all *FMR1* and *FMR2* FMs (Supplementary Figure 1c).

293         Of these parameters, using the IM/PM threshold for *FMR1* and *FMR2* genotype analysis  
294 and performing exSTRa's BWA analysis with controls were useful in detecting refractory STR  
295 expansions. We fed these improved results into the classifier. In both Isaac- and BWA-aligned  
296 training datasets, EH\_v2 at the root node correctly classified all but one FM and most of the non-  
297 FM alleles (Figures 1a and 2a). The classifier's precision, recall, and F1-score in the Isaac- and  
298 BWA-aligned test datasets were 83, 100, and 91% and 90, 100, and 95% to detect FMs and 100,  
299 98, and 99% and 100, 99, and 99% to detect non-FMs, respectively. The ROC and precision-  
300 recall plots are shown in Figures 1b and 2b. The ROC\_AUC metric for cross-validation was  
301  $95.14 \pm 5.12\%$  for Isaac and  $96.99 \pm 3.72\%$  for BWA. All six STR analysis tools contributed to  
302 the performance of the classifier on the improved results of Isaac-aligned GS (Figure 1c), and all  
303 but GangSTR contributed to the performance of the classifier on the BWA-aligned GS (Figure  
304 2c). Among the STR tools, EH\_v2 ranked first in both Isaac and BWA alignments. This model  
305 on the optimized results of STR algorithms performed significantly better, detecting all FMs.  
306 The decision rules that emerged from this analysis suggest the best approach to categorizing FMs  
307 is to support EH\_v2 and/or EH\_v3 FM calls with (at least) one other tool (STRetch,  
308 TREDPARSE, exSTRa, or GangSTR for Isaac, and STRetch or exSTRa for BWA).  
309 Unsurprisingly, we also noticed a drop in precision due to the increase in FP counts, possibly  
310 precipitated by the inaccurate identification of *FMR1* PM and some IM alleles.

## 311 **Analysis of Known Disease STR Loci in Clinical NGS Data**

312 All our patient ES and GS data were BWA-aligned, so we followed the decision tree model  
313 generated on the BWA-aligned EGA and simulated GS datasets, which suggested using EH\_v2  
314 and/or EH\_v3 in addition to STRetch or exSTRa. We added some additional disease STR loci to  
315 the EH\_v2 variant catalog (Supplementary Table 4), analysing a total of 21 disease STRs using  
316 all four tools in our patient cohort.

317 First, we identified 16 EH\_v2 FM expansions that were supported by at least one of  
318 EH\_v3, STRetch, or exSTRa. Of the samples that were not called as expanded by EH\_v2, we  
319 screened for positive calls in EH\_v3, STRetch, and exSTRa outputs. STRetch and exSTRa,  
320 which had higher FP call rates in the EGA and simulated datasets, identified 298 and 442 disease  
321 STR in our patient cohort. Therefore, any positive calls made on these two tools needed to be  
322 supported by either EH\_v2 or EH\_v3. In total, we identified 27 samples, 17 with FM expansions  
323 of the *AR*, *ATXN1*, *ATXN2*, *ATXN8*, *DMPK*, *FXN*, *HTT*, or *TBP* locus, nine with IM or PM  
324 alleles in the *FMRI* locus, and one with a borderline allele in the *ATXN2* locus (summarized in  
325 Table 4). Supplementary Table 11 shows the EH\_v2, EH\_v3, STRetch, and exSTRa results of  
326 the identified STR candidates.

327 We found that most probands with an identified STR candidate inherited the allele from a  
328 parent, except for the *ATXN1* FM in a proband (890-P) with 39 repeats (Supplementary Table  
329 11) compared to the parental *ATXN1* NL alleles that had 28 to 31 repeats (data not shown). The  
330 inherited expansions either remained unchanged or decreased by one or a few repeat units or  
331 increased by 1 to ~15 repeats during intergenerational transmission. We also found seven FM  
332 expansions in parents that were not inherited by the proband.



333 All individuals who tested negative in their molecular assessments for *FMRI*, *FXN*, *SCA*,  
334 or *DMPK* FM expansions were also categorized as non-expanded by our bioinformatics  
335 workflow (data not shown). In the ES data of the proband (2010-P) and his mother (2010-M)  
336 with DM1 and a *DMPK* FM (>50 repeats) finding on molecular assessment, EH\_v2, EH\_v3, and  
337 exSTRa identified the FM expansion. However, the repeat length estimated by EH\_v2 and  
338 EH\_v3 in 2010-P and 2010-M was ~50 repeats, which is significantly lower than the molecular  
339 findings of 150 repeats in 2010-P and 430 repeats in 2010-M (Supplementary Table 11). After  
340 including OTS to EH's analysis of the *DMPK* locus, the FM estimate of EH\_v2 and EH\_v3 was  
341 ~80 repeats (data not shown).

342 Based on the repeat lengths estimated by EH\_v2 and EH\_v3, we categorized the  
343 identified FMs as reduced- or full-penetrance (Table 4; the different repeat size ranges associated  
344 with reduced- and full-penetrance of the STR expansion disorders are summarized in  
345 Supplementary Table 4). Nine of the FMs we identified in the probands and parents were in the  
346 fully-penetrant repeat size range, with another five in the reduced-penetrance range. The *AR* FM  
347 in a proband (1901-P) and her father (1901-F) was categorized as full-penetrance by EH\_v3 (38  
348 repeats) and reduced-penetrance by EH\_v2 (37 repeats).

349 We performed PCR-based molecular tests to verify the expansion status of a subset of the  
350 identified FMs (molecular findings summarized in the last column of Table 4 and Supplementary  
351 Table 11). The *HTT* FMs identified by EH\_v2 (37 repeats), EH\_v3 (37 repeats), STRetch, and  
352 exSTRa in a proband (1530-P) and his father (1530-F) were concordant with the molecular test  
353 ( $37 \pm 1$  repeats). Also, the *AR* FMs in a father (1901-F) and proband (1905-P) identified by  
354 EH\_v2 (37 repeats), EH\_v3 (38 repeats), and STRetch were consistent with the PCR result ( $37 \pm$   
355 1 repeats). On the other hand, the *TBP* FM in a mother (1992-M) identified by EH\_v2 (52

356 repeats) and EH\_v3 (53 repeats) could not be verified by PCR ( $37 \pm 1$  repeats). For the other  
357 identified FMs with an unknown STR expansion status, we are currently performing molecular  
358 validation.

359 Lastly, we investigated the genotype calls of the disease STRs made by EH\_v2, EH\_v3,  
360 and GangSTR in our patient ES and GS datasets to see if the NL allele frequency distribution at  
361 these loci agreed with the reported population frequencies of NL alleles (Supplementary Figures  
362 4 and 5, and Supplementary Table 12). In general, the repeat length distribution pattern of the  
363 STR alleles for most loci was consistent across the ES (Supplementary Figure 4) and GS  
364 (Supplementary Figure 5) data, except for the *FMR1* and *FMR2* loci, which were characterized  
365 inconsistently in the ES data. EH\_v3 genotyped fewer *ATXN8* alleles and also had a different  
366 repeat length distribution profile for the *ATXN7* and *HTT* loci in the ES data. For the *CSTB* locus,  
367 more 1-repeat genotype calls were made by the tools in the ES data, while we found none in the  
368 GS data. More than half of the individuals in our clinical cohort are of European ancestry, so we  
369 compared the frequency of the three most common alleles ascertained in the GS data to the  
370 common NL allele in the Caucasian population reported in the literature (Supplementary Table  
371 12). Except for a few loci, the repeat lengths of the most common alleles determined by the tools  
372 were generally in good agreement with the reported repeat length of the common NL allele in the  
373 Caucasian population.

## 374 **DISCUSSION**

375 The contribution of STR expansions to disease is just beginning to be understood. Hitherto, ~40  
376 neurological disorders have been found to have a causal STR expansion mutation underlying  
377 their pathogenesis<sup>2</sup>, with some recent studies reporting the identification of novel pathogenic  
378 STR expansions through NGS or the more advanced third-generation long-read sequencing

379 technologies<sup>31-35</sup>. The challenges in detecting and characterizing the repeat lengths of STR  
380 expansions in short-read NGS are well recognized<sup>36</sup>. However, recent algorithmic improvements  
381 facilitate the detection of STR expansions that exceed read and/or fragment lengths, providing us  
382 the opportunity to analyze a larger panel of known disease STR loci simultaneously through ES  
383 and GS<sup>1; 10-14</sup>. Some of these methods may also be useful in scanning the entire genome or exome  
384 for novel disease-causing STR expansions<sup>11; 13</sup>.

385         Of the available STR algorithms, EH, GangSTR, and TREDPARSE are particularly  
386 valuable for identifying disease-causing expansions because these programs leverage evidence  
387 beyond the reads that span an STR, enabling the genotyping of larger repeat expansions. Other  
388 methods like STRetch and exSTRa detect STR expansions but do not reliably genotype them  
389 (STRetch) or do not genotype them at all (exSTRa).

390         Our assessment of the performance of these STR tools on GS datasets with known repeat  
391 expansions mapped using two different aligners, Isaac and BWA, showed that the choice of  
392 aligner impacts the sensitivity of GangSTR and exSTRa. GangSTR performed better on Isaac  
393 alignments, whereas exSTRa performed better on BWA alignments.

394         Generally, of all the analysed disease STR loci, the detection of homozygous *FXN* FMs  
395 and the GC-rich *FMRI* and *FMR2* FMs were the most challenging. We modified some  
396 parameters to increase the FM detection potential at these loci and found that exSTRa's  
397 sensitivity improved with control datasets, detecting all *FXN*, *FMRI*, and *FMR2* FMs in the  
398 BWA-aligned data. Also, reducing the repeat length thresholds from FM to PM/IM size ranges  
399 enabled the detection of *FMRI* and/or *FMR2* FMs with EH\_v2, EH\_v3, and TREDPARSE.  
400 Using this reduced cut-off also might detect some IM and PM carriers who, although not  
401 affected, may be at risk of having affected children if their IM/PM allele is highly unstable

402 and/or susceptible to late-onset conditions<sup>37</sup>. Early detection and genetic counselling of these at-  
403 risk individuals might, therefore, help IM/PM allele carriers make informed reproductive  
404 decisions and avoid affected pregnancies<sup>37</sup>.

405 The ML decision tree analysis on the STR results generated using the afore-mentioned  
406 parameter modifications detected all FMs with EH\_v2 and/or EH\_v3 with support from one  
407 other tool (STRetch, TREDPARSE, exSTRa, or GangSTR for Isaac, and STRetch or exSTRa for  
408 BWA). EH contributed significantly to the better overall performance of the classifier on both  
409 Isaac and BWA alignments. Applying these decision rules to our clinical cohort, we identified 27  
410 individuals with an expansion in a known disease STR locus. Of these, 17 individuals had an FM  
411 expansion of the *AR*, *ATXN1*, *ATXN2*, *ATXN8*, *DMPK*, *FXN*, *HTT*, or *TBP* locus, nine  
412 individuals had an *FMR1* allele in the IM or PM size range, and one individual had a borderline  
413 *ATXN2* allele.

414 Using our approach, we were able to confirm the presence of a clinically-validated  
415 *DMPK* FM in the ES data of a proband and his mother with DM1 and also confirm the inherited  
416 *HTT* and *AR* FM in two families using clinical PCR and capillary electrophoresis. We classified  
417 a *TBP* FM detected by EH\_v2 and EH\_v3, but unverified by PCR, as a false-positive.

418 Importantly, none of the 68 individuals who previously had a negative clinical *FMR1*, *FXN*,  
419 *SCA*, or *HTT* test result were falsely-identified as “expanded” by our computational workflow.

420 For the analysis of the *DMPK* locus with EH (the default catalog file of which does not  
421 include OTS), we recommend including OTS as this could result in a significant improvement in  
422 the repeat length estimation, particularly in the GS data, and yield clinically-relevant  
423 information. Although the threshold for defining pathogenic *DMPK* FMs that cause DM1 is only  
424 50 repeats, the different clinical forms of DM1 (mild, classic, and congenital), associated with

425 varying severity and age of onset of symptoms, are caused by *DMPK* FMs in the range of 50-  
426 ~150, ~100~1000, and >1000 repeat units, respectively<sup>38</sup>. We show that with OTS, EH performs  
427 better at sizing *DMPK* FMs that ranged from ~130 to over 2000 repeats in the EGA GS data and  
428 yields estimates that correlate better with the FM repeat lengths in these individuals  
429 (Supplementary Figure 6).

430 Although the methods presented in this study perform well in detecting and sizing FMs,  
431 for some disease STR loci, the difference between a non-FM and an FM, or between a reduced-  
432 penetrance and full-penetrance FM is only a few repeat units, making it difficult to discriminate  
433 these borderline alleles of clinical significance. This limitation is also inherent to PCR-based  
434 tests as DNA polymerase slippage during STR amplification may result in under- or over-  
435 estimation of an STR's size by one or two repeat units<sup>39</sup>.

436 In summary, implementation of a clinical bioinformatics workflow, such as the approach  
437 outlined in this study, to screen for STR expansions in ES and GS data can help identify disease-  
438 associated variants that would otherwise have gone undetected, promote cascade testing, and  
439 improve diagnostics and treatment/management of repeat expansion disorders.

440 **ACKNOWLEDGMENTS**

441           We would like to thank all the CAUSES and IMAGINE Study investigators. CAUSES  
442 Study investigators include Shelin Adam, Christele Du Souich, Alison Elliott, Anna Lehman, Jill  
443 Mwenifumbo, Tanya Nelson, Clara van Karnebeek, and Jan Friedman. The CAUSES Study is  
444 funded by Mining for Miracles, British Columbia Children’s Hospital Foundation, and Genome  
445 British Columbia. IMAGINE Study investigators include Patricia Birch, Madeline  
446 Couse, Colleen Guimond, Anna Lehman, Jill Mwenifumbo, Clara van Karnebeek, and Jan  
447 Friedman. The IMAGINE study is supported by the Canadian Institutes of Health  
448 Research (CIHR – SCA-145104) through CHILD-BRIGHT (Child Health Initiative Limiting  
449 Disability – Brain Research Improving Growth and Health Trajectories), with additional support  
450 provided by BC Children's Hospital Foundation and the Michael Smith Foundation for Health  
451 Research (MSFHR). Indhu Shree Rajan Babu is supported by the MSFHR Research Trainee  
452 Award. We thank the Rare Disease Foundation for funding our research on developing a  
453 bioinformatics pipeline to analyse STRs in next-generation sequencing data (Grant # 2332). We  
454 thank Compute Canada for the Research Allocation Competitions allocation, which facilitated  
455 our analysis of the IMAGINE and EGA genomes, and Julia Handra for coordinating the STR  
456 molecular testing of the clinical samples.

457 **REFERENCES**

- 458 1. Tang, H., Kirkness, E.F., Lippert, C., Biggs, W.H., Fabani, M., Guzman, E., Ramakrishnan,  
459 S., Lavrenko, V., Kakaradov, B., Hou, C., et al. (2017). Profiling of Short-Tandem-  
460 Repeat Disease Alleles in 12,632 Human Whole Genomes. *Am J Hum Genet* 101, 700-  
461 715.
- 462 2. Sznajder, L., and Swanson, M.S. (2019). Short Tandem Repeat Expansions and RNA-  
463 Mediated Pathogenesis in Myotonic Dystrophy. *Int J Mol Sci* 20.
- 464 3. Paulson, H. (2018). Repeat expansion diseases. *Handb Clin Neurol* 147, 105-123.
- 465 4. Salcedo-Arellano, M.J., Dufour, B., McLennan, Y., Martinez-Cerdeno, V., and Hagerman, R.  
466 (2020). Fragile X syndrome and associated disorders: Clinical aspects and pathology.  
467 *Neurobiol Dis* 136, 104740.
- 468 5. Mila, M., Alvarez-Mora, M.I., Madrigal, I., and Rodriguez-Revenga, L. (2018). Fragile X  
469 syndrome: An overview and update of the FMR1 gene. *Clin Genet* 93, 197-205.
- 470 6. Nelson, D.L., Orr, H.T., and Warren, S.T. (2013). The unstable repeats--three evolving faces  
471 of neurological disease. *Neuron* 77, 825-843.
- 472 7. Semaka, A., Creighton, S., Warby, S., and Hayden, M.R. (2006). Predictive testing for  
473 Huntington disease: interpretation and significance of intermediate alleles. *Clin Genet* 70,  
474 283-294.
- 475 8. Mirkin, S.M. (2006). DNA structures, repeat expansions and human hereditary disorders. *Curr*  
476 *Opin Struct Biol* 16, 351-358.
- 477 9. Wallace, S.E., and Bean, L.J. Resources for Genetics Professionals—Genetic Disorders  
478 Caused by Nucleotide Repeat Expansions and Contractions. 2017 Mar 14 [Updated 2019  
479 Nov 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews*®

- 480 [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from:  
481 <https://www.ncbi.nlm.nih.gov/books/NBK535148/>.
- 482 10. Dolzhenko, E., van Vugt, J.J.F.A., Shaw, R.J., Bekritsky, M.A., van Blitterswijk, M., Narzisi,  
483 G., Ajay, S.S., Rajan, V., Lajoie, B.R., Johnson, N.H., et al. (2017). Detection of long  
484 repeat expansions from PCR-free whole-genome sequence data. *Genome Res* 27, 1895-  
485 1903.
- 486 11. Dashnow, H., Lek, M., Phipson, B., Halman, A., Sadedin, S., Lonsdale, A., Davis, M.,  
487 Lamont, P., Clayton, J.S., Laing, N.G., et al. (2018). STRetch: detecting and discovering  
488 pathogenic short tandem repeat expansions. *Genome Biol* 19, 121.
- 489 12. Tankard, R.M., Bennett, M.F., Degorski, P., Delatycki, M.B., Lockhart, P.J., and Bahlo, M.  
490 (2018). Detecting Expansions of Tandem Repeats in Cohorts Sequenced with Short-Read  
491 Sequencing Data. *Am J Hum Genet* 103, 858-873.
- 492 13. Mousavi, N., Shleizer-Burko, S., Yanicky, R., and Gymrek, M. (2019). Profiling the genome-  
493 wide landscape of tandem repeat expansions. *Nucleic Acids Res.*
- 494 14. Dolzhenko, E., Deshpande, V., Schlesinger, F., Krusche, P., Petrovski, R., Chen, S., Emig-  
495 Agius, D., Gross, A., Narzisi, G., Bowman, B., et al. (2019). ExpansionHunter: A  
496 sequence-graph based tool to analyze variation in short tandem repeat regions.  
497 *Bioinformatics.*
- 498 15. Gymrek, M., Golan, D., Rosset, S., and Erlich, Y. (2012). lobSTR: A short tandem repeat  
499 profiler for personal genomes. *Genome Res* 22, 1154-1162.
- 500 16. Willems, T., Zielinski, D., Yuan, J., Gordon, A., Gymrek, M., and Erlich, Y. (2017).  
501 Genome-wide profiling of heritable and de novo STR variations. *Nat Methods* 14, 590-  
502 592.



- 503 17. Highnam, G., Franck, C., Martin, A., Stephens, C., Puthige, A., and Mittelman, D. (2013).  
504 Accurate human microsatellite genotypes from high-throughput resequencing data using  
505 informed error profiles. *Nucleic Acids Res* 41, e32.
- 506 18. Mousavi, N., Shleizer-Burko, S., Yanicky, R., and Gymrek, M. (2019). Profiling the genome-  
507 wide landscape of tandem repeat expansions. *Nucleic Acids Res* 47, e90.
- 508 19. Dolzhenko, E., Deshpande, V., Schlesinger, F., Krusche, P., Petrovski, R., Chen, S., Emig-  
509 Agius, D., Gross, A., Narzisi, G., Bowman, B., et al. (2019). ExpansionHunter: a  
510 sequence-graph-based tool to analyze variation in short tandem repeat regions.  
511 *Bioinformatics* 35, 4754-4756.
- 512 20. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat*  
513 *Methods* 9, 357-359.
- 514 21. Gymrek, M., Willems, T., Reich, D., and Erlich, Y. (2017). Interpreting short tandem repeat  
515 variations in humans using mutational constraint. *Nat Genet* 49, 1495-1501.
- 516 22. Raczy, C., Petrovski, R., Saunders, C.T., Chorny, I., Kruglyak, S., Margulies, E.H., Chuang,  
517 H.Y., Källberg, M., Kumar, S.A., Liao, A., et al. (2013). Isaac: ultra-fast whole-genome  
518 secondary analysis on Illumina sequencing platforms. *Bioinformatics* 29, 2041-2043.
- 519 23. Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler  
520 transform. *Bioinformatics* 25, 1754-1760.
- 521 24. [https://gatk.broadinstitute.org/hc/en-us/articles/360035535912-Data-pre-processing-for-](https://gatk.broadinstitute.org/hc/en-us/articles/360035535912-Data-pre-processing-for-variant-discovery)  
522 [variant-discovery](https://gatk.broadinstitute.org/hc/en-us/articles/360035535912-Data-pre-processing-for-variant-discovery).
- 523 25. Lee, H., Lee, K.W., Lee, T., Park, D., Chung, J., Lee, C., Park, W.Y., and Son, D.S. (2018).  
524 Performance evaluation method for read mapping tool in clinical panel sequencing.  
525 *Genes Genomics* 40, 189-197.

- 526 26. Huang, W., Li, L., Myers, J.R., and Marth, G.T. (2012). ART: a next-generation sequencing  
527 read simulator. *Bioinformatics* 28, 593-594.
- 528 27. Picard Tools. Broad Institute. <http://broadinstitute.github.io/picard/>.
- 529 28. Willems, T., Gymrek, M., Highnam, G., Genomes Project, C., Mittelman, D., and Erlich, Y.  
530 (2014). The landscape of human STR variation. *Genome Res* 24, 1894-1904.
- 531 29. Krzywinski, M., and Altman, N. (2017). Classification and regression trees. *Nature Methods*  
532 14, 757-758.
- 533 30. <https://scikit-learn.org/stable/>.
- 534 31. van Kuilenburg, A.B.P., Tarailo-Graovac, M., Richmond, P.A., Drögemöller, B.I., Pouladi,  
535 M.A., Leen, R., Brand-Arzamendi, K., Dobritzsch, D., Dolzhenko, E., Eberle, M.A., et al.  
536 (2019). Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in. *N Engl J*  
537 *Med* 380, 1433-1441.
- 538 32. Sone, J., Mitsuhashi, S., Fujita, A., Mizuguchi, T., Hamanaka, K., Mori, K., Koike, H.,  
539 Hashiguchi, A., Takashima, H., Sugiyama, H., et al. (2019). Long-read sequencing  
540 identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear  
541 inclusion disease. *Nat Genet* 51, 1215-1221.
- 542 33. Tian, Y., Wang, J.L., Huang, W., Zeng, S., Jiao, B., Liu, Z., Chen, Z., Li, Y., Wang, Y., Min,  
543 H.X., et al. (2019). Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear  
544 Inclusion Disease-Related Disorders. *Am J Hum Genet* 105, 166-176.
- 545 34. Florian, R.T., Kraft, F., Leitão, E., Kaya, S., Klebe, S., Magnin, E., van Rootselaar, A.F.,  
546 Buratti, J., Kühnel, T., Schröder, C., et al. (2019). Unstable TTTTA/TTTCA expansions  
547 in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3. *Nat*  
548 *Commun* 10, 4919.

- 549 35. Corbett, M.A., Kroes, T., Veneziano, L., Bennett, M.F., Florian, R., Schneider, A.L.,  
550 Coppola, A., Licchetta, L., Franceschetti, S., Suppa, A., et al. (2019). Intronic ATTTC  
551 repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to  
552 chromosome 2. *Nat Commun* 10, 4920.
- 553 36. Mantere, T., Kersten, S., and Hoischen, A. (2019). Long-Read Sequencing Emerging in  
554 Medical Genetics. *Front Genet* 10, 426.
- 555 37. Hunter, J.E., Berry-Kravis, E., Hipp, H., and Todd, P.K. FMR1 Disorders. 1998 Jun 16  
556 [Updated 2019 Nov 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors.  
557 GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.  
558 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1384/>.
- 559 38. TD, Bird. Myotonic Dystrophy Type 1. 1999 Sep 17 [Updated 2019 Oct 3]. In: Adam MP,  
560 Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA):  
561 University of Washington, Seattle; 1993-2020. Available from:  
562 <https://www.ncbi.nlm.nih.gov/books/NBK1165/>.
- 563 39. Raz, O., Biezuner, T., Spiro, A., Amir, S., Milo, L., Titelman, A., Onn, A., Chapal-Ilani, N.,  
564 Tao, L., Marx, T., et al. (2019). Short tandem repeat stutter model inferred from direct  
565 measurement of in vitro stutter noise. *Nucleic Acids Res* 47, 2436-2445.

**TABLE 1.** Features of some publicly available STR analysis algorithms.

Features	lobSTR	RepeatSeq	HipSTR	TREDPARSE	ExpansionHunter	STRetch	exSTRa	GangSTR
Outputs repeat length?	Y	Y	Y	Y	Y	Y		Y
Sequencing reads	Single & Paired-end	Single & Paired-end	Single & Paired-end	Paired-end	Paired-end	Paired-end	Paired-end	Paired-end
Sequencing platforms supported	Illumina, Sanger, 454, and IonTorrent	Illumina	Illumina	Illumina	Illumina	Illumina	Illumina	Illumina
Library prep. supported	PCR & PCR-free	n.a.	PCR & PCR-free	PCR & PCR-free	PCR & PCR-free	PCR & PCR-free	PCR & PCR-free	PCR & PCR-free
Library prep. (rcmd)	None	None	None	None	PCR-free	PCR-free	None	None
Aligners (rcmd)	lobSTR, BWA-MEM	Novoalign, Bowtie 2	Indel-sensitive aligner	None	None	None	Bowtie2	None
Analysis approach	Targeted & GW	Targeted & GW	Targeted & GW	Targeted	Targeted	GW	Targeted & GW	Targeted & GW
NGS data type supported	GS	GS	GS	GS	GS	GS & ES	GS & ES	GS & ES
NGS data format	.bam or .fastq/.fasta	.bam	.bam	.bam	.bam or .cram	.bam or .fastq	.bam	.bam
Built-In stutter correction model*	Y		Y	Y				
Test of significance						Y	Y	
Read types used	Spanning	Spanning	Spanning	Spanning, flanking or partial, paired-end reads, IRR	Spanning, flanking, IRR/IRR pairs	Anchored IRR	Flanking, anchored IRR	Spanning, flanking, IRR/IRR pairs
Phasing			Y					
PL	C++	C++	C++	Python	C++	Java	Perl & R	C++
Sizing limitation	RL	RL	RL	FL	Not limited	FL	n.a.	Not limited
Control dataset	Not required	Not required	Not required	Not required	Not required	Required	Not required	Not required
Complex repeats	n.a.	n.a.	n.a.	n.a.	Y	n.a.	n.a.	N
Output files	.vcf, .allelotype.stats	.repeatseq, .calls, .vcf	.vcf	.vcf, .json	.vcf, .json, .log	.tsv	p values, ECDF, tsum plots	.vcf
Customized regions file	Possible	Possible	Possible	Possible	Possible	Possible, but not recommended.	Possible	Possible

\*Corrects the noise (stutters) introduced during PCR amplification-based library preparation

Library prep: library preparation protocol; rcmd: recommended; PL: programming language used

Y: Feature included; N: Feature not included

n.a.: not applicable; GW: genome-wide; GS: genome sequencing; ES: exome sequencing; IRR: in-repeat reads; RL: read-length; FL: fragment-length; Not limited: not limited by either RL or FL; ECDF: Empirical Cumulative Distribution Function; t-sum: aggregated T statistic

**TABLE 2.** Full-mutation (FM) samples detected in the Isaac- and BWA-aligned European Genome-phenome Archive (EGA) and simulated genomes by the STR tools (ExpansionHunter versions 2 and 3 (EH\_v2 and EH\_v3), GangSTR, TREDPARSE, STRetch, and exSTRa) implemented using default parameters. The analysed EGA and simulated dataset had 86 samples with at least one known FM allele. The number of true-positives detected by the tools, sensitivity, and the number of false-positives identified in our default analysis of the Isaac- and BWA-aligned genomes are shown.

	Isaac				BWA			
	Detected FM Samples	True FM Samples	Sensitivity	False-Positives	Detected FM Samples	True FM Samples	Sensitivity	False-Positives
<b>EH_v2</b>	65	86	0.755813953	6	64	86	0.744186047	6
<b>EH_v3</b>	64	86	0.744186047	5	64	86	0.744186047	5
<b>GangSTR</b>	47	86	0.546511628	8	33	86	0.38372093	8
<b>TREDPARSE</b>	62	86	0.720930233	3	62	86	0.720930233	10
<b>STRetch</b>	65	86	0.755813953	26	65	86	0.755813953	26
<b>exSTRa</b>	48	86	0.558139535	33	76	86	0.88372093	35

**TABLE 3.** Classification of the *FMR1* and *FMR2* ExpansionHunter versions 2 and 3 (EH\_v2 and EH\_v3), GangSTR, and TREDPARSE genotype calls using lowered thresholds to detect FMs in the Isaac- and BWA-aligned EGA and simulated genomes of samples with known *FMR1* and *FMR2* FM expansions. The number of FMs misclassified as normal (NL) or intermediate (IM) alleles are shown. The true number (n) of known FM alleles in the *FMR1* and *FMR2* genes is indicated in parenthesis. False-positive (FP) calls made by the tools are also reported.

FM Threshold	Isaac							BWA						
	<i>FMR1</i> (n=18)				<i>FMR2</i> (n=3)			<i>FMR1</i> (n=18)				<i>FMR2</i> (n=3)		
	54 repeats				60 repeats			54 repeats				60 repeats		
Allelic classification	FM	IM	NL	FP	FM	NL	FP	FM	IM	NL	FP	FM	NL	FP
EH_v2	18	.	.	20	3	.	2	18	.	.	16	3	.	0
EH_v3	18	.	.	22	3	.	0	18	.	.	22	3	.	0
GangSTR	4	.	14	7	0	3	0	3	.	15	0	0	3	0
TREDPARSE	15	1	2	8	0	3	0	16	.	2	13	0	3	0

**TABLE 4.** STR candidates identified in our patient cohort. Probands with an identified STR candidate are given a “-P” suffix in the “Sample ID” column, siblings, “-S”, mother, “-M”, and father, “-F”. The genes harboring the STR candidate identified by our bioinformatics workflow and the inheritance pattern deciphered by comparing the proband’s STR call with that of the parents are reported. “Sequencing” column shows the technology used: genome sequencing (GS) or exome sequencing (ES). The “Pathogenic SNV/indel/SV Finding” column indicates whether the proband has had a definite, probable, certain, or no diagnosis of a single nucleotide variant (SNV), indel, or structural variant (SV). Phenotypic presentations reported in the probands, STR Finding from our bioinformatics analysis, and the results from the molecular validation (if available) are also presented.

Sample ID	Gene	Inheritance	Sequencing	Pathogenic SNV/indel/SV Finding	Phenotype detail	STR Finding	Molecular Validation
1901-P	<i>AR</i>	Inherited	GS	No	Short stature, delayed gross motor, speech and language development, spasticity, cerebral palsy, and hypertonia	FM (RP/FP)	FM (RP)
1901-F	<i>AR</i>	.	GS	.	.	.	FM (RP)
890-P	<i>ATXN1</i>	De novo	ES	No	Optic atrophy, findings suggestive of congenital stationary night blindness, growth restriction, no dysmorphic features, and diffuse mild hypomyelination	FM (FP)	Pending
532-M	<i>ATXN1</i>	.	GS	.	.	FM (FP)	Pending
2560-M	<i>ATXN1</i>	.	ES	.	.	FM (FP)	Pending
1411-F	<i>ATXN1</i>	.	ES	.	.	FM (FP)	Pending
821-P	<i>ATXN2</i>	Inherited	ES	No	Mild intellectual disabilities, systemic hypertension, cutis aplasia, congenital heart defect, limb anomalies, significant family history of her father with alopecia, learning problems, early onset hypertension, and differential diagnosis of autosomal dominant Adams-Oliver syndrome	FM (FP)	Pending
821-M	<i>ATXN2</i>	.	ES	.	.	borderline <sup>^</sup>	Pending
1099-P	<i>ATXN8</i>	*	ES	No	Hearing loss, cataract, myopia, visceral (kidney and spleen) cysts, proteinuria, and dysmorphic facial features	FM (RP)	Pending
235-P	<i>ATXN8</i>	Inherited	GS	No	Mild to moderate intellectual disability, history of psychosis, family history: a sister who also has intellectual disability and history of psychosis, and a brother with mild developmental delays	FM (RP)	Pending
235-M	<i>ATXN8</i>	.	GS	.	.	FM (RP)	Pending
2010-P	<i>DMPK</i>	Inherited	ES	Definite	Myotonic dystrophy type 1, inguinal hernias, joint hypermobility, strabismus, mild intellectual disability, and dysmorphic facial features	FM (FP)	FM (FP)
2010-M	<i>DMPK</i>	.	ES	.	.	FM (FP)	FM (FP)
699-M	<i>FMRI</i>	.	GS	.	.	PM	Pending
148-M	<i>FMRI</i>	.	GS	.	.	PM	Pending (Proband is negative for <i>FMRI</i> FM)
800-F	<i>FMRI</i>	.	GS	.	.	IM or PM	Pending
800-P	<i>FMRI</i>	Inherited	GS	Definite	Macrocephaly, seizures, optic nerve hypoplasia, hyporeflexia, profound intellectual disability, cortical visual impairment, and spastic tetraplegia	IM or PM	Pending
480-P	<i>FMRI</i>	Inherited	GS	Probable	Moderate intellectual disability, language delay, autism, borderline macrocephaly, low set ears, down slanting palpebral fissures, high palate, and soft skin	IM or PM	Pending
712-M	<i>FMRI</i>	.	GS	.	.	IM or PM	Pending (Proband is negative for <i>FMRI</i> FM)
925-P	<i>FMRI</i>	Inherited	GS	No	Intellectual disability, developmental delay including speech delay, dysmorphic features, and behavioural challenges	NL or PM	Negative for FM
925-S	<i>FMRI</i>	Inherited	GS	No	Intellectual disability, autism, developmental delay, and dysmorphic features	IM	Pending
925-M	<i>FMRI</i>	.	GS	.	.	PM	Pending
1987-F	<i>FXN</i>	.	GS	.	.	NL/FM	Pending
1530-P	<i>HTT</i>	Inherited	GS	Uncertain	Global developmental delay, seizures, gliosis, developmental regression, encephalomalacia, hirsutism, nystagmus, optic atrophy, cyanosis, abnormal muscle tone, scoliosis, hearing impairment, and otitis media	FM (RP)	FM (RP)
1530-F	<i>HTT</i>	.	GS	.	.	FM (RP)	FM (RP)
1992-M	<i>TBP</i>	.	GS	.	.	FM (FP)	Negative for FM
2990-M	<i>TBP</i>	.	ES	.	.	FM (FP)	Pending

RP: reduced penetrance; FP: full penetrance


\*Father was not tested

<sup>^</sup>RP alleles have 33-34 repeats and FP alleles have  $\geq 37$  repeats


**Figure 1.** Decision tree classification of the STR calls of the Isaac-aligned EGA and simulated genome sequence (GS) data by ExpansionHunter versions 2 and 3 (EH\_v2 and EH\_v3), GangSTR, TREDPARSE, STRetch, and exSTRa using modified parameters. Panel (A) shows the decision tree generated by the classifier on the training dataset. Node #0 at the top of the tree is the root node. Each node lists an STR tool (feature). The “samples” number represents the total number of data points present within a particular node, and “value” shows the number of expanded (or full-mutation or FM) and non-expanded (non-FM) data points. The shade of the colour of each node reflects the proportion of expanded to non-expanded data points, with deeper blue and orange meaning more non-expanded and expanded data points, respectively. Gini index shows the impurity at each node. The terminal nodes shown in the last rows are the leaves. Leaves with a Gini of 0 have data points belonging to either the expanded or the non-expanded class. Panel B shows the ROC and precision-recall plots generated by the classifier on the test dataset. Panel C shows the ranking of the STR tools that contributed to the decision tree model.




A




B



Precision-Recall Curve



C



**Figure 2.** Decision tree classification of the STR calls of the BWA-aligned EGA and simulated GS data by ExpansionHunter versions 2 and 3 (EH\_v2 and EH\_v3), GangSTR, TREDPARSE, STRetch, and exSTRa using modified parameters. The decision tree generated by the classifier on the training dataset (A), ROC and precision-recall plots generated by the classifier on the test dataset (B) and ranking of the STR tools that contributed to the decision tree model (C) are shown.

